Medical professionals report that patients using glucagon-like peptide-1 (GLP-1) receptor agonists, such as Ozempic, Wegovy, and Zepbound, may experience temporary hair loss. According to dermatologists and endocrinologists, this shedding is typically caused by telogen effluvium, a condition where the body halts non-essential functions like hair growth due to physiological stress. Doctors attribute this stress to the rapid weight loss frequently associated with these medications.
The reported hair loss does not occur immediately upon starting the medication but generally begins one to two months after treatment commences. Dr. Daniel Bessesen, a professor of medicine at the University of Colorado Anschutz, stated that patients might notice an increase in hair shedding during washing or brushing. Unlike other forms of hair loss that result in bald patches, telogen effluvium involves thinning across the scalp while hair remains present. Physicians noted that the condition is temporary, usually lasting three to six months.
Dietary habits while on GLP-1s can also influence hair health. Because these medications often reduce appetite, patients may consume less protein, which is a primary component of hair. Dr. Bessesen emphasized the importance of maintaining adequate intake of water and protein to prevent the body from utilizing its own tissue for nutrients. If nutritional deficiencies in iron, vitamin D, or protein are not addressed, the shedding may persist as chronic telogen effluvium. Doctors recommend consulting a dermatologist if hair does not begin to return after several months.
The phenomenon also highlights the importance of nutritional monitoring for patients on these prescriptions. Individuals who experience a sharp decrease in appetite may notice the onset of chronic shedding if they do not deliberately supplement their protein and vitamin intake. This could lead to additional medical appointments with specialists such as dermatologists or registered dietitians to manage nutrient levels. Furthermore, medical experts suggest that if weight loss occurs too rapidly, patients may need to work with their providers to adjust their dosage to mitigate these physiological stressors.
In terms of future policy and healthcare management, the prevalence of this side effect may lead to more standardized guidance for clinicians when prescribing GLP-1s. Patients already managing underlying hair loss conditions should be aware that these medications could potentially worsen existing thinning. As of the current reporting, doctors state that for most patients, hair typically returns to its previous state after about one year of treatment, provided nutritional needs are met and the body adjusts to the medication. No specific legal or regulatory deadlines for changes to drug labeling regarding this side effect were reported.